Results 21 to 30 of about 14,209 (224)

Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis [PDF]

Acta Haematologica, 2020
Immunoglobulin light chain amyloidosis (AL amyloidosis) is a rare, life-threatening disease characterized by the deposition of misfolded proteins in vital organs such as the heart, the lungs, the kidneys, the peripheral nervous system, and the gastrointestinal tract. This causes a direct toxic effect, eventually leading to organ failure. The underlying
Layla Van Doren, Suzanne Lentzsch
openalex   +4 more sources

Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14-Year Experience of an Academic Center. [PDF]

Hematol Oncol
Dima D, Goel U, Ullah F, Faiman B, Basali D, Mazzoni S, Williams LS, Samaras C, Valent J, Anwer F, Khouri J, Raza S.   +11 more
europepmc   +2 more sources

Evaluation of Cytokine Levels in Cardiac Transthyretin and Immunoglobulin Light Chain Amyloidosis and Their Correlation with Myocardial Inflammatory Cells and MACE. [PDF]

Biomedicines
Musigk N, Suwalski P, Müller M, Violano M, Klingel K, Weiner J, Beule D, Landmesser U, Heidecker B.   +8 more
europepmc   +3 more sources

A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils. [PDF]

Nat Commun
Martinez-Rivas G, Ayala MV, Bender S, Codo GR, Swiderska WK, Lampis A, Pedroza L, Merdanovic M, Sicard P, Pinault E, Richard L, Lavatelli F, Giorgetti S, Canetti D, Rinsant A, Kaaki S, Ory C, Oblet C, Pollet J, Naser E, Carpinteiro A, Roussel M, Javaugue V, Jaccard A, Bonaud A, Delpy L, Ehrmann M, Bridoux F, Sirac C.   +28 more
europepmc   +2 more sources

Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting. [PDF]

J Hematol Oncol
Bu Q, Zhu HH, Chen W.
europepmc   +2 more sources

Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. [PDF]

Biol Blood Marrow Transplant, 2018
Nguyen VP, Landau H, Quillen K, Brauneis D, Shelton AC, Mendelson L, Rahman H, Sloan JM, Sarosiek S, Sanchorawala V.   +9 more
europepmc   +3 more sources

Immunoglobulin light chain amyloidosis [PDF]

memo - Magazine of European Medical Oncology, 2021
SummaryImmunoglobulin light chain (AL) amyloidosis is a rare and underdiagnosed life-threatening systemic disease, primarily caused by insoluble depositions of misfolded monoclonal light chains. The monoclonal light chain paraprotein originates from a small clonal B‑cell or a clonal plasma cell population.
Hermine Agis, Maria Theresa Krauth
openalex   +2 more sources

Immunoglobulin light chain amyloidosis presenting as Budd-Chiari syndrome. [PDF]

Hepatol Forum, 2021
Ozercan M, Eser I, Kiremitci S, Peynircioglu B, Karayalcin S, Idilman R.   +5 more
europepmc   +4 more sources

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. [PDF]

Blood Cancer J, 2023
Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D'Souza A.   +5 more
europepmc   +4 more sources

Periorbital Purpura as a Key Diagnostic Clue in Immunoglobulin Light Chain Amyloidosis. [PDF]

JMA J
Miyaue K, Isono H.
europepmc   +2 more sources